Clinical Trial Detail

NCT ID NCT03422393
Title Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Choi
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Venetoclax

Age Groups: adult senior

No variant requirements are available.